Morgan Stanley downgrades Novo Nordisk, citing semaglutide patent cliff

Morgan Stanley downgraded Novo Nordisk to Underweight from Equal-weight on Sept. 11, 2026, keeping a price target of 250 Danish crowns, about $40 per New York-listed share, and citing the company's reliance on semaglutide plus the patent cliff ahead ^[1][3].

Analyst Thibault Boutherin and colleagues wrote that Novo's valuation does "not entirely" reflect subdued mid-term growth and "the implications of the semaglutide patent cliff on Novo's terminal value" ^[1]. The price target implies more than 10% downside from the last close ^[1].

The shares fell 2.6% in early Copenhagen trading after the note ^[1]. A German market report described a drop of about 2.8% to 278.2 Danish kroner ^[2]. Novo's US-listed ADRs closed at $44.02 on Sept. 11 and traded around $43.02 the next session, down about 2.27%, with a market value of roughly $190.10 billion ^[2].

Semaglutide, the molecule in Ozempic and Wegovy, accounted for about 75% of Novo's sales in 2026, according to the bank ^[1][2][3]. Morgan Stanley models it at 59% of sales in 2031, when the loss of exclusivity begins to bite ^[1][3]. The sources describe the timing slightly differently: Morgan Stanley points to loss of exclusivity across Europe and the US in the early-to-mid 2030s ^[1], while TheStreet, citing Morningstar, puts European patent expiry in 2031 and US expiry in 2032 ^[3].

The bank forecasts 2% to 3% revenue and operating profit growth in 2027, roughly in line with consensus, and a 4% compound annual growth rate from 2027 to 2030 — below the 4% revenue and 7% EBIT growth it expects from European pharmaceutical companies broadly ^[1]. It credits Novo's oral obesity franchise with reaching $10 billion in sales by 2031 but says that "will not be enough to offset pricing and competitive headwinds" ^[1].

A Morgan Stanley survey of 200 primary care physicians found growing GLP-1 adoption in diabetes and obesity but also market share losses for Novo over the next 18 months to Eli Lilly's current products and its upcoming retatrutide, expected in 2027 ^[1]. On valuation, the analysts said Novo trades at 12.5 times 2027 estimated earnings, a 7% discount to European large pharma peers and a 35% premium to global peers facing their own loss-of-exclusivity issues, such as Sanofi and GSK ^[1].

Other analysts are less negative. Novo carries a consensus Hold rating — four Buy, fourteen Hold and one Sell — with a consensus price target of $64.94 ^[2]. HSBC kept a Hold rating and raised its target to 320 Danish kroner from 300 ^[2][3]. JPMorgan raised its target in late August while staying neutral, and Goldman Sachs left its rating and target unchanged ^[3].

Novo's own guidance for fiscal 2026, given in August, points to adjusted revenue and operating profit of 0 to minus 6% at constant exchange rates ^[2][3]. Second-quarter gross margin slipped to 78.2% from 82.7% a year earlier, and Wegovy injection sales fell 22% ^[3]. Semaglutide patents have already lapsed in Canada and Brazil, which the company named as a drag on this year's outlook ^[3]. Novo told investors in August it was serving roughly 46 million patients ^[3]. The company also halted two Phase III heart failure trials of ziltivekimab (HERMES and ATHENA) after an independent monitoring committee judged their prospects poor; a third program, ARTEMIS, continues with data expected in the first half of 2027 ^[2].

Why it matters for patients

The patent cliff weighing on Novo's valuation is also the mechanism that tends to make a drug cheaper. Generic competitors typically arrive at a fraction of the branded price, and for a drug taken by tens of millions of people that represents a very large price cut in the early 2030s ^[3]. Nothing in the downgrade changes what semaglutide costs today: no change to supply, insurance coverage or pharmacy availability has been announced ^[1][2][3].

Which treatments exist in the coming years is a separate question from Novo's share price. The ziltivekimab heart failure setbacks remove one non-obesity path for the company ^[2], and Eli Lilly's retatrutide, expected in 2027, is one source of the share pressure Morgan Stanley models ^[1].

What generic semaglutide will cost in the US, whether it will reach the market on the timeline the analysis assumes, and how insurers would cover it have not been reported.

What happens next

Novo has called an employee town hall for Sept. 15, 2026, with an internal invitation promising "an exciting update about our company's next chapter" ^[3]. The company holds a capital markets day in London on Sept. 21, 2026, from 09:00 to 15:30 BST, where management is expected to discuss strategy, the R&D pipeline, business operations and performance ^[2][3]. Morgan Stanley says it sees "limited scope for major announcements" at that event ^[1]. One source lists Sept. 21 as Novo's next earnings date ^[2], while TheStreet reports third-quarter results are due Nov. 4 according to Novo's investor calendar ^[3].

Looking further out, Morgan Stanley places the start of loss of exclusivity in 2031 ^[1], with Morningstar-cited dates of 2031 for Europe and 2032 for the US ^[3]. Ziltivekimab data from the ARTEMIS trial is expected in the first half of 2027 ^[2], and retatrutide is expected in 2027 ^[1].